dilated and hypertrophic cardiomyopathies, 13, 14 and cathecolaminergic polymorphic ventricular tachycardia. 15 In the current study, we aimed to use the emerging hiPSC technology to establish an in vitro model of ARVC. We Background-Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a primary heart muscle disorder resulting from desmosomal protein mutations. ARVC is characterized pathologically by fibrofatty infiltration and clinically by arrhythmias and sudden cardiac death. We aimed to establish a patient-/disease-specific human induced pluripotent stem cell (hiPSC) model of ARVC. Methods and Results-Dermal fibroblasts were obtained from 2 patients with ARVC with plakophilin-2 (PKP2) mutations, reprogrammed to generate hiPSCs, coaxed to differentiate into cardiomyocytes (CMs), and then compared with healthy control hiPSC-derived CMs (hiPSC-CMs). Real-time polymerase chain reaction showed a significant decrease in the expression of PKP2 in the ARVC-hiPSC-CMs. Immunostainings revealed reduced densities of PKP2, the associated desmosomal protein plakoglobin, and the gap-junction protein connexin-43. Electrophysiological assessment demonstrated prolonged field potential rise time in the ARVC-hiPSC-CMs. Transmission electron microscopy identified widened and distorted desmosomes in the ARVC-hiPSC-CMs. Clusters of lipid droplets were identified in the ARVC-CMs that displayed the more severe desmosomal pathology. This finding was associated with upregulation of the proadipogenic transcription factor peroxisome proliferator-activated receptor-γ. Exposure of the cells to apidogenic stimuli augmented desmosomal distortion and lipid accumulation. The latter phenomenon was prevented by application of a specific inhibitor of glycogen synthase kinase 3β (6-bromoindirubin-3'-oxime). Conclusions-This study highlights the unique potential of the hiPSC technology for modeling inherited cardiac disorders in general and ARVC specifically. The hiPSC-CMs were demonstrated to recapitulate the ARVC phenotype in the dish, provide mechanistic insights into early disease pathogenesis, and provide a unique platform for drug discovery and testing in this disorder. 
A rrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable primary cardiac muscle disorder characterized by the replacement of cardiomyocytes (CMs), primarily in the right ventricle (RV), by fibrofatty tissue. 1, 2 The resulting disruption of normal myocardial architecture can lead to RV dysfunction, life-threatening arrhythmias, and sudden cardiac death. Causative mutations have been identified in a significant number of patients, mainly in genes encoding for proteins associated with mechanical cell junctions (plakoglobin, plakophilin, desmoglein, desmocollin, and desmoplakin). 3, 4 Mutated gene products were shown to be involved in remodeling of the intercalated disc.
Clinical Perspective on p 568
Significant insights into ARVC pathogenesis have been gained in the past decade from several clinical, genetic, and pathological studies in patients with ARVC 5 and from relevant mouse models. 6 Nevertheless, among the hurdles in studying the disease process has been the inability to study viable human CMs from patients with ARVC. The introduction of the induced pluripotent stem cell (iPSC) technology 7 may provide a possible solution to this challenge. The human iPSC (hiPSC) approach allows reprogramming of adult somatic cells into pluripotent stem cells by expression of a set of transcription factors. 8 Recent studies demonstrated the robust ability to generate hiPSCs and to coax their differentiation into the cardiac lineage. 9, 10 More recent studies showed the ability to establish disease-/patient-specific hiPSCs that can model disease-specific abnormalities in several inherited cardiac disorders such as different variants of the long-QT syndrome, hypothesized that CMs differentiating from the ARVChiPSCs will recapitulate the disease phenotype and that investigation of these cells may provide new insights into the disease process.
Materials and Methods
An expanded description of the methods used for genomic sequencing, teratoma formation, karyotype analysis, immunostainings, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, gene expression analysis, microelectrode array recordings, and transmission electron microscopy is provided in the online-only Data Supplement.
Establishment and CM Differentiation of the ARVC-hiPSCs
All studies were approved by the Helsinki committee of Rambam Medical Center, Haifa, Israel. Dermal fibroblasts were isolated from a small skin biopsy obtained after the patients' informed consent. The hiPSCs were established by retroviral delivery of Oct4, Sox-2, and Klf-4 followed by valproic acid treatment as described. 11, 16 Several ARVC-hiPSC clones, which were positively stained with vital Tra-I-60 staining, were selected and expanded. Undifferentiated hiPSC colonies were cultured on mouse embryonic fibroblasts as previously described. 11, 16 Culture medium consisted of 80% knockout high-glucose glutamine-free DMEM with sodium pyruvate supplemented with 20% serum replacement, L-glutamine 1 mmol/L, mercaptoethanol 0.1 mmol/L, bFGF 4 ng/mL, and 1% nonessential amino acids (Invitrogen).
CM differentiation of the ARVC and healthy control hiPSCs was induced using the embryoid body (EB) differentiating system. 17 Briefly, undifferentiated hiPSCs were dispersed into small cell clumps using collagenase IV (300 U/mL for 45 minutes; Life Technologies) and cultivated in suspension for 10 days as EBs. The EBs were plated on 0.1% gelatin-coated culture dishes. Spontaneously contracting area was microdissected and used for phenotypic characterization.
Adipogenic Medium
In some of the studies, the hiPSC-derived CMs (hiPSC-CMs) were cultured in an adipogenic-promoting medium. Adipogenesis was promoted in a similar manner to that reported previously [18] [19] [20] [21] with slight modifications. Briefly, microdissected control and ARVC-hiPSCCMs (at 30 days of differentiation) were treated with 20% fetal bovine serum-containing media supplemented with 10 μg/mL insulin (Biological Industries, Israel), 0.5 mmol/L 3-isobutyl-1-methylxanthine (Sigma-Aldrich), 2.5 μmol/L dexamethasone (Sigma-Aldrich), and StemPro LipoMax 20 (1:200) for 3 days. Fresh media containing 20% FBS supplemented with insulin (10 μg/mL) and StemProLipoMax (1:200) was then replaced every other day for an additional 14 days. In the experiments evaluating GSK-3β inhibition, 10 µmol/L of 6-bromoindirubin-3'-oxime (BIO; Sigma-Aldrich) was added.
Statistical Analysis
Continuous variables are reported as mean±SEM. Categorical variables are expressed as frequencies. Differences between group means were compared using the Mann-Whitney U test (except for differences between drug treatment and baseline in which the Wilcoxon test was used). Comparison between lipid accumulation and desmosomal gap width quartiles was conducted using the χ 2 for trend analysis. Receiver operating characteristic curve analysis was used to assess the sensitivity and specificity of desmosomal gap width as a marker and a predictor of lipid droplet accumulation. To this aim, desmosomal gap width was used as a continuous variable (width measured in nm), and lipid droplet accumulation within the same cell was used as a categorical binary value. Receiver operating characteristic curve analysis was conducted using SPSS-16. We calculated the area under the curve, also known as concordance statistic, to assess discrimination. A value of P<0.05 was considered statistically significant.
Results

Generation of the ARVC Patient-Specific hiPSCs
Dermal fibroblasts were obtained from a 30-year-old man diagnosed previously with ARVC according to the 2010 task force criteria for ARVC. 22 Clinically, the patient presented with episodes of rapid palpitations, near-syncope, and a family history of sudden cardiac death. His baseline ECG revealed typical T-wave inversions in leads V1 through V3 ( Figure 1A) . Episodes of ventricular tachycardia were also recorded, displaying a left bundle branch block-like morphology ( Figure 1B) . Echocardiographic examination and RV ventriculography revealed a dilated and trabeculated RV with reduced global RV function and segmental wall motion abnormalities. Electroanatomic mapping of the RV identified large areas with reduced voltage ( Figure 1C) , a finding previously shown to correlate with the diseased RV regions. 23 Genetic analysis identified a heterozygous insertion of T in position 972 in exon 3 of the plakophilin-2 (PKP2) gene (c.972InsT/N), resulting in a frame shift from amino acid 324 to a stop codon in position 335 (A324fs335X). This mutation has not been previously reported. The patient's fibroblasts were reprogrammed to generate the patient-specific ARVC-hiPSCs by retroviral delivery of Oct3/4, Sox2, and Klf4. Similar hiPSCs previously created from fibroblasts of a healthy individual using an identical reprogramming strategy served as controls. 16 Sequencing of the affected allele ( Figure  1D ) verified that the PKP2 mutation was present in the ARVChiPSC colonies but not in healthy control cells.
The ARVC-hiPSC colonies displayed typical human embryonic stem cell morphology (Figure 2A , left), were stained positively for the pluripotent markers Oct-4, NANOG, SSEA-4, and Tra-I-60 (Figure 2A ), displayed alkaline phosphatase activity ( Figure 2B ), and maintained a normal karyotype. Pluripotency of the ARVC-hiPSCs was verified by the presence of cell derivatives of all 3 germ layers in in vitro differentiating EBs, as manifested by the positive staining for Desmin (mesoderm), α-fetoprotein (endoderm), and nestin (ectoderm; Figure 2C ). Similarly, injection of undifferentiated ARVC-hiPSCs into SCID-beige mice led to the formation of teratomas containing advanced tissue derivatives of all 3 germ layers ( Figure 2D ). Finally, ARVC-hiPSCs showed silencing of the 3 retroviral transgenes ( Figure 2E ) and reactivation of endogenous pluripotency genes (NANOG, FOXD3, and OCT4; Figure 2F ), indicating successful reprogramming.
CM Differentiation
The EB differentiation system was used to coax the differentiation of the hiPSCs into the cardiac lineage (Movie I in the onlineonly Data Supplement). Real-time quantitative polymerase chain reaction (PCR) analysis showed comparable levels of expression of cardiac-specific genes in the ARVC and healthy control hiPSC-CMs and minimal expression of these genes in the undifferentiated cells ( Figure 3A) . Similarly, immunostainings of the sarcomeric proteins cardiac troponin I and α-actinin ( Figure 3B ) confirmed the CM phenotype of the differentiating hiPSC-CMs.
Extracellular multielectrode array recordings established the presence of cardiac-specific electric activity by the ARVC-hiPSC-CMs ( Figure 3C ) and the development of a functional syncytium with pacemaker activity and action potential propagation ( Figure 3D ; Movie II in the onlineonly Data Supplement). Adequate chronotropic responses to adrenergic and cholinergic stimuli were noted after application of 10 μmol/L isoproterenol (increase in beating frequency by 156±55%; P<0.05; n=5) and 1 μmol/L carbamylcholine (decrease in beating frequency by 45±12%; P<0.05; n=5).
Automated analysis of the field potential rise time, previously suggested as a surrogate marker for the cellular action potential rise time, 24 revealed significant prolongation of this parameter in the ARVC-hiPSC-CMs compared with healthy control cells (11.5±2.6 versus 4.1±1.3 ms, respectively; P<0.05; Figure 3E ). Finally, analysis of the corrected field potential duration revealed a slightly prolonged corrected field potential duration in ARVC-hiPSC-CMs, which was not statistically significant compared with healthy control cells (0.36±0.02 seconds versus 0.42±0.03 seconds).
Immunostaining for Desmosomal and Gap-Junction Proteins
Because the mutations associated with ARVC involve mainly desmosomal proteins, we initially performed real-time quantitative PCR analysis evaluating the expression of the relevant genes in ARVC and healthy control hiPSC-CMs. These studies revealed a significant reduction in the expression of PKP2 in the ARVC-CMs compared with healthy control cells (P<0.01). In contrast, no significant reductions were noted in the expression of the associated desmosomal genes JUP (plakoglobin) and DSP (desmoplakin; Figure 4A ).
We next performed immunostainings, targeting the desmosomal proteins in small cell clusters of both healthy control and ARVC-hiPSC-CMs ( Figure 4B ). We initially focused on the evaluation of the staining pattern of PKP2 ( Figure 4B , top). Note the typical membranous punctuate staining pattern for PKP2 in the healthy control hiPSC-CMs ( Figure 4B , top left) and the diminished PKP2 immunosignal in the ARVC-CMs ( Figure 4B , top right). Thus, as expected from the nature of the PKP2 mutation in the patient with ARVC, quantitative analysis revealed a significant reduction in the density of the PKP2 immunosignal (expressed as percentage of the total CM cellular area) in the ARVC-hiPSC-CMs compared with healthy control cells (2.2±0.6% versus 9.5±3.6%; P<0.05; Figure 4C , top).
In a similar manner, immunostaining analysis for the structurally associated desmosomal protein plakoglobin (also known as γ-catenin) revealed a significant reduction (P<0.05) in the immunofluorescent signal area density in the ARVC (1.0±0.1%) compared with healthy control (7.4±0.9%) CMs ( Figure 4B and 4C, middle). Finally, we also evaluated the effect of the PKP2 mutation on the associated intercalated disc structure, gap junction. Interestingly, immunofluoresence analysis, targeting the major gap-junction protein connexin-43 (Cx43), revealed a significant reduction in the Cx43 immunofluorescent signal in the ARVChiPSC-CMs compared with healthy control cells (3.4±0.9% versus 0.9±0.4%; P<0.05; Figure 4B and 4C, bottom).
Ultrastructural Analysis
To further evaluate the effect of the PKP2 mutation on the ultrastructural properties of the differentiated ARVC-hiPSCCMs, we performed transmission electron microscopy analysis of the ARVC and healthy control cells at 40 days of differentiation. Both control and ARVC CMs exhibited large quantities of myofibrils organized into typical sarcomeres by parallel Z bands ( Figure 5A and 5B). Interestingly, in 33% (13 of 39) of the ARVC-hiPSC-CMs studied, we could identify the presence of clusters of lipid droplets accumulating within the cytoplasm ( Figures 5B, 5E , and 6B). Such a phenomenon was not observed in any of the healthy control hiPSC-CMs.
We next focused on the ultrastructural properties of the desmosomes in the hiPSC-CMs and noted significant morphological differences between healthy control ( Figure 5A and 5C) and ARVC ( Figure 5B , 5D, and 5E) CMs. This was manifested by the presence of variable degrees of structural distortion of desmosomes in the ARVC-CMs but not in the healthy control cells. Note the hazy, pale, and dissymmetric appearance of the ARVC desmosomes and the widened desmosomal gaps in the examples provided ( Figure 5B , 5D, and 5E). To quantify the degree of desmosomal abnormalities in the ARVC-hiPSCCMs, we performed quantitative morphometric assessment of the desmosomal dimensions in both the ARVC and control CMs ( Figure 5C and 5D ). This analysis revealed a significant increase in the desmosomal internal gap width (32±2 versus 24±1 nm; P<0.05) and the total external desmosomal width (171±12 versus 101±5 nm; P<0.01) in the ARVC-hiPSC-CMs compared with healthy control cells ( Figure 5F and 5G) .
Strikingly, the degree of desmosomal abnormalities seemed to correlate with the accumulation of lipid droplets within the ARVC-CMs. This can be appreciated in Figures 5B and 6B , in which the presence of severe desmosomal distortion was associated with intracellular accumulation of clusters of lipid droplets. In contrast, ARVC-CMs showing minimal desmosomal abnormalities did not contain similar clusters ( Figure 6A ).
To further evaluate the relationship between desmosomal abnormalities and accumulation of lipid droplets in the ARVC-hiPSC-CMs, we graded the degree of desmosomal abnormalities in each cell using the average measured desmosomal gap width within the cell. We then divided all cells into 4 quartiles based on this parameter and compared the percentage of cells containing lipid droplet clusters in each group. As depicted in Figure 6C , lipid accumulation was correlated with desmosomal gap widening quartiles (P<0.05). To further assess whether desmosomal abnormalities can predict the presence of lipid accumulation within the cells, we generated a receiver operating characteristic curve. Evaluation of the area under the receiver operating characteristic curve demonstrated a significant correlation between desmosomal gap widening and lipid accumulation (area under the curve=0.84; 95% confidence interval, 0.73-0.94; n=50) with an optimal cutoff value of 25.9 nm ( Figure 6D) .
Finally, we also evaluated, using real-time PCR analysis, the expression level of the master proadipogenic transcription factor peroxisome proliferator-activated receptor-γ. This analysis revealed >4× increase in the expression levels of peroxisome proliferator-activated receptor-γ in the ARVChiPSC-CMs compared with healthy control cells, suggesting the activation of the adipogenic signaling pathway in these cells ( Figure 5H ).
Confirmation of the Pathological Findings in a Second ARVC Patient
To evaluate whether the molecular and ultrastructural properties described above may be applicable to other patients with ARVC carrying alternative PKP2 mutations, we generated a second patient-specific hiPSC line. Dermal fibroblasts were obtained from a 22-year-old patient with ARVC displaying the characteristic RV pathology and ventricular arrhythmias ( Figure IA CMs were then derived from the ARVC-B hiPSCs using the same EB-based differentiating technique, and the generated beating areas were also stained positively for cardiac 
Vulnerability to Apoptosis
Apoptosis has been proposed as 1 of the mechanisms mediating CM loss in ARVC in both in vitro 18 and in vivo 26 studies.
To assess for the presence of apoptosis, we performed terminal deoxynucleotidyl transferase dUTP nick end labeling analysis of both ARVC and healthy control hiPSC-CMs after exposure to serum starvation, a well-known stimulator of apoptosis. The results of these studies revealed a significantly higher percentage of apoptotic cells in the ARVC-hiPSC-CMs (3.8±1%; n=7; P<0.05; Figure V in the online-only Data Supplement) compared with healthy control cells (1.0±0.6%).
Effect of Adipogenic Stimulus
CMs derived from ARVC animal models were suggested to display a tendency toward adipogenesis. 18 To evaluate whether ARVC-hiPSC-CMs recapitulate such a propensity, we exposed healthy control and ARVC-hiPSC-CMs to a combination of 3-isobutyl-1-methylxanthine, dexamethasone, and insulin in conjunction with lipid supplementation (MDI-Lipo). Treated healthy control cells exhibited minimal or no lipid droplet accumulation with preserved desmosomal and sarcomeric structures ( Figure 7A ). In contrast, the treated ARVC-hiPSC-CMs displayed extensive lipid droplet accumulation throughout most of the cytoplasm. Interestingly, this lipid accumulation was associated with paucity of desmosomal structures ( Figure 7B) .
Finally, we also evaluated whether the accumulation of lipid droplets in the ARVC-CMs after the adipogenic medium challenge could be prevented. Because previous studies implied that reduced canonical Wnt pathway signaling may be associated with the ARVC phenotype and lipid droplet accumulation, 18 we aimed to determine the activity level of this pathway in the ARVC-hiPSC-CMs. To this end, we analyzed in both ARVC and control hiPSC-CMs the nuclear density of β-catenin; an immunostaining assay previously suggested to serve as a surrogate marker for canonical Wnt pathway activity. 27 Our results ( Figure VI in the onlineonly Data Supplement) revealed a significant reduction in the nuclear density of β-catenin in the ARVC-hiPSC-CMs (5.2±1.5%) compared with healthy control CMs (12.1±1.8%; P<0.05; n=7), suggesting reduced Wnt activity in the former cells.
Next, to evaluate whether activation of the canonical Wnt pathway can reverse the lipid droplet accumulation, we treated the ARVC-hiPSC-CMs simultaneously with the adipogenic media with BIO (10 µmol/L), a specific inhibitor of GSK-3β. This compound, a known activator of the canonical Wnt pathway, was previously shown to prevent lipid accumulation in vitro in cardiac progenitor cells derived from an ARVC mouse model. 28 Application of BIO did not affect sarcomeric organization in the ARVC-CMs and did not seem to significantly alter desmosomal abnormalities in these cells. Thus, quantitative ultrastructural analysis revealed that both desmosomal internal gap width (36±2 versus 39±5 nm) and external desmosomal width (169±21 versus 214±34 nm) did not significantly change after the addition of BIO to the adipogenic medium ( Figure 7C ). Similarly, a comparable low number of desmosomal structures were found in the ARVC-CMs treated with the adipogenic medium with or without simultaneous exposure to BIO (0.9±0.2 versus 1.4±0.6 desmosomes/cell). Importantly, in contrast to the lack of significant effects of BIO on the desmosomes, its application had a dramatic effect in preventing intracellular lipid droplet buildup in the ARVC-hiPSC-CMs as can be appreciated in the example in Figure 7D .
Discussion
In the current study, we evaluated the ability of the hiPSC technology to model ARVC and provide mechanistic insights into the human disease process. Patient-specific hiPSCs were created from 2 patients with a clinical diagnosis of ARVC and genetic evidence for PKP2 mutations.
By studying CMs differentiating from the ARVC-hiPSCs and comparing them with healthy control cells, we were able to (1) identify significant desmosomal abnormalities in the ARVC-hiPSC-CMs in both the electron microscopy studies and the PKP2 and plakoglobin immunostaining analysis; (2) demonstrate the effect of desmosomal remodeling on the associated intercalated disc structure gap junction; (3) reveal the accumulation of lipid droplets in many of the ARVC-CMs and the upregulation of the proadipogenic transcription factor peroxisome proliferator-activated receptor-γ; (4) identify a clear correlation between the degree of desmosomal abnormalities in the ARVC-CMs and the probability for lipid accumulation in the same cells; (5) show that ARVC-CMs have an increased vulnerability to apoptosis; and (6) demonstrate the ability of lipogenic stress to worsen the ARVC phenotype in terms of lipid droplet accumulation and the ability of the small molecule BIO (an inhibitor of GSK-3β) to suppress the latter effect.
A major breakthrough in the understanding of ARVC came with the realization that this syndrome is associated with mutations in desmosomal proteins. 3, 4 Besides confirming the genetic nature of the disease (autosomal dominant inheritance with variable penetrance), this discovery fueled several studies attempting to uncover the relationship between such mutations, the resulting desmosomal structural abnormalities, and the eventual ARVC pathological and clinical findings. 3, 18, [29] [30] [31] Consistent with these findings, we also identified in the 2 patients studied (both presenting with a highly arrhythmogenic phenotype and advanced RV pathology) mutations in the PKP2 gene. Both the novel mutation identified in our first patient (c.972InsT) and the previously reported mutation identified in the second patient (c.148_151delACAG/N) resulted in an early stop codon. As expected from the nature of such mutations (leading to a truncated protein), these allelic derangements resulted in a significant reduction in the density of the PKP2 immunosignal in the ARVC-hiPSC-CMs. Interestingly, we could also identify a reduction in the mRNA levels of PKP2 in the ARVC-hiPSC-CMs. This finding most probably results from a nonsense-mediated mRNA decay mechanism. 32 Importantly, in both patients, the in vitro ARVC-hiPSC-CM model was able to recapitulate the abnormal desmosomal phenotype, thought to be at the center of ARVC pathogenesis. This was manifested in the ultrastructural analysis of the ARVC-hiPSC-CMs by the presence of significant desmosomal abnormalities resembling those previously reported in patients with ARVC and murine models. 3, 30, 33 Similarly, a significant reduction was noted in the density of the immunosignals of PKP2 and the structurally associated desmosomal protein plakoglobin in the ARVC-hiPSC-CMs. The latter finding is in agreement with the work of Asimaki et al, 34 who observed a significant reduction in the immunosignal of both proteins in endomyocardial biopsies of patients with ARVC and with a recent study using a similar ARVC-hiPSC model. 35 In healthy myocardium, plakoglobin is found mainly at junctional plaques, and the cytoplasmic concentration of plakoglobin is kept low because of proteasomal degradation. In ARVC, the plakoglobin signal level at junctional plaques is diffusely reduced, 34, 36 and plakoglobin is thought to accumulate in the cytosolic pool, from which it can diffuse into the nucleus and alter gene expression. 37 The translocation of plakoglobin to the cytosolic and nuclear pools is thought to result in an attenuated spatial concentration at the desmosomes, translating to the reduced immunosignal identified in the current and previous studies 34, 36 at these membranous structures. In this regard, it is interesting to note that our real-time PCR data revealed an unaltered expression of plakoglobin at the mRNA level in both patients, despite the observed decrease in its membranous immmunosignal levels, a finding that also supports the aforementioned hypothesis of desmosomal disintegration leading to cytoplasmic translocation of plakglobin.
Recent studies suggest that abnormalities in the desmosomal proteins in ARVC may also affect other related components of the intercalated disc, including gap junctions and sodium channels. 29, 38 Supporting these previous observations, our results show a significant reduction in gap-junction density (as suggested from the Cx43 immunofluorescent analysis) in the ARVC-hiPSC-CMs compared with healthy control cells. To evaluate whether these structural findings translate into functional derangements, we quantified the field potential rise time in both ARVC and control CMs. Halbach et al, 24 using simultaneous microelectrode extracellular recordings and intracellular action potential measurements from embryonic CMs, previously demonstrated that the field potential rise time highly correlates with action potential rise time and that reduced excitability and conduction can be identified by prolongation of this parameter. Consequentially, the presence of significantly prolonged field potential rise time in the ARVC-hiPSC-CMs suggests reduced excitability or conduction slowing in these cells and may contribute to the increased arrhythmogenesis observed in patients with ARVC, even before the development of significant ventricular structural alterations.
Another important finding of the current study relates to the identification of clusters of lipid droplets within many (approximately one third) of the ARVC-hiPSC-CMs. Consistent with this finding, we also observed a significant increase in the expression of the master proadipogenic transcription peroxisome proliferator-activated receptor-γ in the ARVC-CMs. Furthermore, we were able to demonstrate a functional proadipogenic state of the ARVC-CMs, as suggested by the robust lipid accumulation after exposure to a lipogenic media. The latter finding is in agreement with the recent article of Kim et al, 39 which also found that ARVC-hiPSC-CMs (derived from patients with ARVC with different PKP2 mutations) are prone to lipid accumulation after treatment with various adipogenic stimuli. 39 Although lipid accumulation is considered one of the hallmarks of ARVC, there is uncertainty whether this is because of intramyocardial lipid accumulation or fibrofatty replacement of necrotic myocardial tissue. Intra-CM lipid accumulation was previously shown only in rodent models 3, 18, 40 and in a few human myocardial specimens analyzed by electron microscopy. 41, 42 Finally, the results of our study imply that a proadipogenic state of the diseased CMs resulting in intramyocardial lipid accumulation may have at least a partial role in ARVC disease pathogenesis. Interestingly, the effect of the adipogenic stimuli on the ARVC-CMs could be prevented by activation of the canonical Wnt pathway in these cells by the small molecule BIO, a specific inhibitor of GSK-3β. This effect may be explained by the inherent reduced canonical Wnt pathway signaling in the ARVC-CMs as demonstrated by the reduced density of nuclear β-catenin in our study. In addition, these results are in agreement with the work of Lombardi et al, 28 who demonstrated that a similar treatment could prevent lipid accumulation in cardiac progenitor cells derived from a mouse model of ARVC.
One of the key novel findings of the current study was the fact that intracellular lipid droplet accumulation could be predicted based on the degree of desmosomal abnormalities in the same cell. The relationship among the mutations in desmosomal genes, desmosomal structural abnormalities, and the resulting fibrofatty myocardial phenotype in ARVC has been a long-standing enigma of the disease pathogenesis. A potential mechanism that may explain the tight relationship identified in our study between desmosomal abnormalities and lipid accumulation may be derived from recent findings by the Marian's group. 18, 28, 43 These studies suggest a crosstalk between desmosomal disintegration and a proadipogenic state. Plakoglobin (γ-catenin) was pinpointed as a key mediator of this crosstalk, dislodging from the disintegrated abnormal desmosomes and inhibiting the canonical Wnt pathway because of its resemblance to β-catenin, consequentially promoting a proadipogenic state. 18 Despite the unique advantages of the hiPSC approach for modeling inherited cardiac disorders in general and ARVC specifically, as highlighted in this study, this strategy still possesses some inherent limitations such as the inability to study pathological phenomena at the whole-organ and systemic levels. This may be important, for example, for studying the potential mechanistic role of inflammation in ARVC. 44 Similarly, other factors that may play a role in ARVC pathogenesis, such as multicellular interactions, the 3-dimensional properties of the tissue, and external mechanical forces, cannot be modeled currently using the hiPSC-CM system. Further advancements in the field of in vitro cardiac tissue engineering, however, may provide a possible solution to these challenges. 45 An additional limitation stems from the relatively early stage phenotype of the hiPSC-CMs, which may not adequately represent the adult pathology. In this regard, it is interesting to note that recent studies suggested a potential role for early differentiating cardiac cells in ARVC pathogenesis. 31, 43 In addition, significant efforts are currently made in the field by several groups in an attempt to devise strategies to induce hiPSC-CM maturation.
Despite the aforementioned limitations, our data demonstrate the unique ability of the hiPSC technology to model ARVC. Using this approach, we showed that some of the key features of ARVC, namely, desmosomal-related pathology and lipid accumulation, can be identified in the ARVC-hiPSCCMs. This study also provides important mechanistic insights into the cardiac pathology in ARVC as well as confirming some of the existing theories in patient-specific human tissues. Finally, the generated model system provides a unique platform to evaluate existing as well as novel therapeutic strategies for ARVC.
